Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26083503 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Edmond Nicolae Barcan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Petru Rares 2, 200349 Craiova, Romania. Hauptthemen laut MEDLINE: Glioblastoma, Receptor Protein-Tyrosine Kinases, Brain Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii, University of Medicine and Pharmacy of Craiova, Romania, UEFISCDI, Bucharest.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain tumor characterized by molecular complexity and resistance to conventional treatments, including surgery, radiation, and chemotherapy. Despite these challenges, advancements in receptor tyrosine kinase (RTK) research, combined with multi-omics approaches, hold promise for improving patient outcomes and survivability. RTKs are central to GBM progression, influencing cell proliferation, survival, and angiogenesis. However, the complexity of RTK signaling necessitates a broader, integrative perspective, which has been enabled by the emergence of -omics sciences. Multi-omics technologies—including genomics, transcriptomics, proteomics, and metabolomics—offer unprecedented insights into the molecular landscape of GBM and its RTK-driven pathways. Genomic studies have revealed mutations and amplifications in RTK-related genes, while transcriptomics has uncovered alterations in gene expression patterns, providing a clearer picture of how these aberrations drive tumor behavior. Proteomics has further delineated changes in protein expression and post-translational modifications linked to RTK signaling, highlighting novel therapeutic targets. Metabolomics complements these findings by identifying RTK-associated metabolic reprogramming, such as shifts in glycolysis and lipid metabolism, which sustain tumor growth and therapy resistance. The integration of these multi-omics layers enables a comprehensive understanding of RTK biology in GBM. For example, studies have linked metabolic alterations with RTK activity, offering new biomarkers for tumor classification and therapeutic targeting. Additionally, single-cell transcriptomics has unveiled intratumoral heterogeneity, a critical factor in therapy resistance. This article highlights the transformative potential of multi-omics in unraveling the complexity of RTK signaling in GBM. By combining these approaches, researchers are paving the way for precision medicine strategies that may significantly enhance diagnostic accuracy and treatment efficacy, providing new hope for patients facing this devastating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Petru Rares 2, 200349 Craiova, Romania.
- Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
- Department of Neurology, University of Medicine and Pharmacy of Craiova, Petru Rares 2, 200349 Craiova, Romania.
- Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Petru Rares 2, 200349 Craiova, Romania.
- Department of Neurosurgery, Clinical Emergency Hospital "Bagdasar-Arseni", Soseaua Berceni 12, 041915 Bucharest, Romania.
- Department of Neurosurgery, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
ORCID-Profile: Edmond Nicolae Barcan, Carmen Duta, Georgiana Adeline Staicu, Oana Alexandru, Alexandra Costachi, Irina Stoian, Ligia Gabriela Tataranu
Förderung
- Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii
- University of Medicine and Pharmacy of Craiova, Romania
- UEFISCDI, Bucharest
Zitieren
APA
Barcan, E. N., Duta, C., Staicu, G. A., Artene, S. A., Alexandru, O., Costachi, A., Pirvu, A. S., Tache, D. E., Stoian, I., Popescu, S. O., Tataranu, L. G., & Dricu, A. (2025). Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083503
Vancouver
Barcan EN, Duta C, Staicu GA, Artene SA, Alexandru O, Costachi A, et al. Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083503
BibTeX
@article{Barcan2025,
author = {Barcan, Edmond Nicolae and Duta, Carmen and Staicu, Georgiana Adeline and Artene, Stefan Alexandru and Alexandru, Oana and Costachi, Alexandra and Pirvu, Andreea Silvia and Tache, Daniela Elise and Stoian, Irina and Popescu, Stefana Oana and Tataranu, Ligia Gabriela and Dricu, Anica},
title = {Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26083503}
}
EUVIMED